Back to Search Start Over

Stratification of Outcomes After Transcatheter Aortic Valve Replacement According to Surgical Inoperability for Technical Versus Clinical Reasons

Authors :
Brian Whisenant
Mauricio G. Cohen
Howard C. Herrmann
Samir R. Kapadia
Gregory P. Fontana
Wen Cheng
Paul S. Teirstein
Mathew R. Williams
Tarun Chakravarty
David Cohen
Hasan Jilaihawi
Vasilis Babaliaros
Craig R. Smith
Ke Xu
Susheel Kodali
E. Murat Tuzcu
Joseph E. Bavaria
Martin B. Leon
John G. Webb
Vinod H. Thourani
Michael J. Mack
Raj Makkar
Augusto D. Pichard
Alfredo Trento
Source :
Journal of the American College of Cardiology. (9):901-911
Publisher :
American College of Cardiology Foundation. Published by Elsevier Inc.

Abstract

ObjectivesThe goal of this study was to examine the impact of reasons for surgical inoperability on outcomes in patients undergoing transcatheter aortic valve replacement (TAVR).BackgroundPatients with severe aortic stenosis may be deemed inoperable due to technical or clinical reasons. The relative impact of each designation on early and late outcomes after TAVR is unclear.MethodsPatients were studied from the inoperable arm (cohort B) of the randomized PARTNER (Placement of Aortic Transcatheter Valve) trial and the nonrandomized continued access registry. Patients were classified according to whether they were classified as technically inoperable (TI) or clinically inoperable (CLI). Reasons for TI included porcelain aorta, previous mediastinal radiation, chest wall deformity, and potential for injury to previous bypass graft on sternal re-entry. Reasons for CLI were systemic factors that were deemed to make survival unlikely.ResultsOf the 369 patients, 23.0% were considered inoperable for technical reasons alone; the remaining were judged to be CLI. For TI, the most common cause was a porcelain aorta (42%); for CLI, it was multiple comorbidities (48%) and frailty (31%). Quality of life and 2-year mortality were significantly better among TI patients compared with CLI patients (mortality 23.3% vs. 43.8%; p < 0.001). Nonetheless, TAVR led to substantial survival benefits compared with standard therapy in both inoperable cohorts.ConclusionsPatients undergoing TAVR based solely on TI have better survival and quality of life improvements than those who are inoperable due to clinical comorbidities. Both TI and CLI TAVR have significant survival benefit in the context of standard therapy. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894)

Details

Language :
English
ISSN :
07351097
Issue :
9
Database :
OpenAIRE
Journal :
Journal of the American College of Cardiology
Accession number :
edsair.doi.dedup.....6ba97665678835128d56f3dfa1f2072a
Full Text :
https://doi.org/10.1016/j.jacc.2013.08.1641